Cargando…

The impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy: a randomized controlled trial

BACKGROUND: This study evaluated the impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy. METHODS: Older breast cancer survivors were randomized into two groups: combined training: resistance + aerobic exercise program for nine mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Paulo, Thais R. S., Rossi, Fabricio E., Viezel, Juliana, Tosello, Giuliano T., Seidinger, Sylvia C., Simões, Regina R., de Freitas, Ruffo, Freitas, Ismael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339353/
https://www.ncbi.nlm.nih.gov/pubmed/30658629
http://dx.doi.org/10.1186/s12955-019-1090-4
Descripción
Sumario:BACKGROUND: This study evaluated the impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy. METHODS: Older breast cancer survivors were randomized into two groups: combined training: resistance + aerobic exercise program for nine months (n = 18) or control group (n = 18). Quality of life was assessed by the questionnaires SF36, EORTC QLQ-C30, and EORTC QLQ-BR23 at baseline, and at three, six, and nine months. The exercise group performed 40 min of resistance exercises on machines followed by 30 min of aerobic training on a treadmill 3x/wk. Repeated measures ANOVA was used to compare the groups over time. RESULTS: Significant time x group interactions and moderate to high effect sizes were found for physical functioning, physical health, bodily pain, general health perception, vitality, social functioning, fatigue, sleep disturbance, body image, and upset by hair loss, favoring the exercise group. CONCLUSION: This study demonstrated the potential benefits and high clinical relevance of exercise programs to improve quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy.